lancet-header
Preprints with The Lancet is part of SSRN´s First Look, a place where journals and other research experts identify content of interest prior to publication. These preprint papers are not peer-reviewed and are posted here as part of a 12-month trial. Authors have either opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet, or submitted directly via SSRN. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. These papers should not be used for clinical decision making or reporting of research to a lay audience without indicating that this is preliminary research that has not been peer-reviewed. For more information see the Comment published in The Lancet, or visit The Lancet┬┤s FAQ page, and for any feedback please contact preprints@lancet.com

Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial

54 Pages Posted: 9 Apr 2019

See all articles by Yoav Domany

Yoav Domany

University of Cincinnati, College of Medicine, Department of Psychiatry & Behavioral Neuroscience; Tel Aviv Sourasky Medical Centre - Department of Psychiatry; Tel Aviv University - Sackler Faculty of Medicine

Jadienne Lord

University of Cincinnati, College of Medicine, Department of Psychiatry & Behavioral Neuroscience

Cheryl B. McCullumsmith

University of Toledo

More...

Abstract

Background: suicidal patients are often presented to the Emergency Department, where specific treatment is lacking. Ketamine, a rapidly acting antidepressant with anti-suicidal properties might offer relief.

Methods: thirty eligible participants who suffered acute suicidal ideation and required hospitalization were randomized to intranasal ketamine 40mg or placebo, between August 2016 to April 2018. Safety and efficacy evaluations were scheduled for two and four hours, on days 1, 3, 7, and 21 post administration. Primary outcome was suicidal ideation four hours post administration. Randomization was carried out by the pharmacist while the rest of the study group was blinded.

Outcomes: Fifteen subjects were randomised for ketamine and fifteen for control, all were analyzed for primary and secondary outcomes. Four hours post administration the mean difference in suicidal symptoms between the groups, measured by the Montgomery-├ůsberg Depression Rating Scale (MADRS) item of suicidal thoughts, was 1.267 (95% confident interval 0.1-2.43, P<0.05) favoring the ketamine group, with suicidal ideation remission rates of 80% of the ketamine group compares with 33% of the controls (p<0.05). The mean difference in depressive symptoms, measured by MADRS, at the same time was 9.75 (95% confident interval 0.72-18.79, P<0.05) favoring the ketamine group. The treatment was safe and well-tolerated.

Interpretation: Intranasal ketamine alleviated suicidal ideation and improved depressive symptoms four hours post ketamine administration. We present an innovative paradigm for the management of suicidal individuals in emergency setting. Future larger-scale studies are warranted to establish treatment recommendation.

Trial Registration Number: ClinicalTrials.gov Identifier: NCT02183272.

Funding Statement: This study was supported by the American Foundation of Suicide Prevention.

Declaration of Interests: All authors declare no conflict of interests.

Ethics Approval Statement: This study was reviewed and approved by the University of Cincinnati Institutional Review Board.

Keywords: suicide, ketamine, emergency department, suicidal ideation

Suggested Citation

Domany, Yoav and Lord, Jadienne and McCullumsmith, Cheryl B., Intranasal Ketamine for Alleviation of Acute Suicidal Ideation. An Emergency Department, Trans-Diagnostic Approach: Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial (April 5, 2019). Available at SSRN: https://ssrn.com/abstract=3367057

Yoav Domany (Contact Author)

University of Cincinnati, College of Medicine, Department of Psychiatry & Behavioral Neuroscience ( email )

CARE/Crawley Building, Suite E-870
3230 Eden Avenue
Cincinnati, OH
United States

Tel Aviv Sourasky Medical Centre - Department of Psychiatry ( email )

Tel Aviv
Israel

Tel Aviv University - Sackler Faculty of Medicine ( email )

Tel Aviv University
Ramat Aviv, 69978
Israel

Jadienne Lord

University of Cincinnati, College of Medicine, Department of Psychiatry & Behavioral Neuroscience

CARE/Crawley Building, Suite E-870
3230 Eden Avenue
Cincinnati, OH
United States

Cheryl B. McCullumsmith

University of Toledo

Mail Stop 119, HH 3000
Toledo, OH 43606
United States

Click here to go to TheLancet.com

Paper statistics

Abstract Views
155
Downloads
36